GoodRx Holdings, Inc. Class A Common Stock
Here’s whether GoodRx Holdings, Inc. Class A Common Stock (GDRX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+0.58% over 10 days); 3-month momentum positive (+11.8%). Concerns: trading below the 200-day MA (long-term downtrend); RSI 71 — overbought, elevated pullback risk; weak 1-year return of -45.0%. Currently 56.1% off its 52-week high. Score: -1/7.
GDRX is trading below its 200-day MA ($3.15) — a key warning sign the longer-term trend is under pressure. With an RSI of 71.3, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -45.0% compares to +27.9% for SPY (trailed the market by 72.9%). The current 56.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.